Minami, Y., Shimamura, T., Shah, K., Laframboise, T., Glatt, K. A., Liniker, E., Borgman, C., Haringsma, H., Feng, W., Weir, B., Lowell, A., Lee, J. C., Wolf, J., Shapiro, G., Wong, K.-K., Meyerson, M., & Thomas, R. K. (2007). The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ ERBB2 inhibitor HKI-272. Oncogene, 26(34), 5023-5027.